Tango Therapeutics Stock Falls After $210 Million Equity Offering - Tokenist
Summary
Tango Therapeutics priced a $210 million underwritten public offering and added about $15 million through a PIPE, bringing total gross financing to roughly $225 million. The market reacted negatively, and the stock fell sharply on dilution concerns. The company develops precision cancer medicines, so the news is relevant to the software and biotech innovation ecosystem only at a broader industry level. Institutional investors took part in the deal, and the company expects the transactions to close subject to customary conditions. The article also highlights Tango’s pipeline and the potential upside analysts still see in the shares.
Funding
Amount
$210.0M
Total raised
Date
October 23, 2025
Announcement date
Investors
Logos Capital, Invus, Farallon Capital Management, Balyasny Asset Management, Adage Capital Management
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected